羟基红花黄色素A的药理作用及研究进展

牛芬溪, 刘悦, 刘雅楠, 张硕峰, 方芳

中国药学杂志 ›› 2021, Vol. 56 ›› Issue (17) : 1372-1377.

PDF(1127 KB)
PDF(1127 KB)
中国药学杂志 ›› 2021, Vol. 56 ›› Issue (17) : 1372-1377. DOI: 10.11669/cpj.2021.17.003
综述

羟基红花黄色素A的药理作用及研究进展

  • 牛芬溪, 刘悦, 刘雅楠, 张硕峰, 方芳*
作者信息 +

Reseach Progress on Pharmacological Effects and Mechanisms of Hydroxysafflor Yellow A

  • NIU Fen-xi, LIU Yue, LIU Ya-nan, ZHANG Shuo-feng, FANG Fang*
Author information +
文章历史 +

摘要

羟基红花黄色素A(hydroxysafflor yellow A,HSYA)是中药红花活血通经、散瘀止痛功效相关的有效成分之一,也是注射用红花黄色素的主要有效成分。近年来从分子-细胞-动物多角度对HSYA的药理作用及机制进行了深入探讨,发现除抗心肌缺血作用外,其还具有抗脑缺血、改善认知,抗帕金森病、降血糖、抗癌、改善肺、肝、肾及骨组织功能等多种药理作用,本文综述了近年来HSYA的药理作用及机制研究进展,为临床应用和新药开发提供科学依据。

Abstract

Hydroxysafflor yellow A (HSYA) is one of the active ingredients of flowers of Carthamus tinctorius L. safflower, which is related with its efficacy of blood activating and dredging channels, breaking blood stasis and relieving pain. HSYA is also the main components of the HSYA injection approved to treat the stable angina pectoris due to heart blood stasis and obstruction. Recently, the pharmacological effect and mechanism of HSYA have been studied base on the molecular-cell-animals level, which showed HSYA has multiple effects besides anti-myocardial ischemia injury, such as anti-cerebral ischemia, improving cognition, anti-Parkinson disease,lowering blood glucose, anti-tumor, improving the function of live, lung, kidney and bone, etc. This paper reviews the relevant pharmacological effects and mechanism of HSYA in order to provide science evidences for clinical application and further development of HSYA.

关键词

红花 / 羟基红花黄色素A / 药理作用 / 作用机制

Key words

Carthamus tinctorius L. flowe safflower / hydroxysafflor yellow A / pharmacological effect / mechanism

引用本文

导出引用
牛芬溪, 刘悦, 刘雅楠, 张硕峰, 方芳. 羟基红花黄色素A的药理作用及研究进展[J]. 中国药学杂志, 2021, 56(17): 1372-1377 https://doi.org/10.11669/cpj.2021.17.003
NIU Fen-xi, LIU Yue, LIU Ya-nan, ZHANG Shuo-feng, FANG Fang. Reseach Progress on Pharmacological Effects and Mechanisms of Hydroxysafflor Yellow A[J]. Chinese Pharmaceutical Journal, 2021, 56(17): 1372-1377 https://doi.org/10.11669/cpj.2021.17.003
中图分类号: R965   

参考文献

[1] WU Z H. Research progress summary of Chinese medicine safflower [J]. World Latest Med Inf(世界最新医学信息文摘), 2019, 19(34): 33-34.
[2] HUANG Z C. Clinical study on early angina pectoris after acute myocardial infarction [J]. World Latest Med Inf(世界最新医学信息文摘), 2019, 19(55): 93-96.
[3] ZHOU M X, FU J H, ZHANG Q, et al. Effect of hydroxyl safflower yellow A on myocardial apoptosis after acute myocardial infarction in rats [J]. Genet Mol Res, 2015, 14 (2): 3133-3141.
[4] MENG Z, SONG M Y, LI C F, et al. shRNA interference of NLRP3 inflammasome alleviate ischemia reperfusion-induced myocardial damage through autophagy activation [J]. Biochem Biophys Res Commun, 2017, 494(3-4): 728-735.
[5] YE J X, WANG M, WANG R Y, et al. Hydroxysafflor yellow A inhibits hypoxia/ reoxygenation-induced cardiomyocyte injury via regulating the AMPK/NLRP3 inflammasome pathway [J]. Int Immunopharmacol, 2020, 82: 106316.
[6] STEPHANOU A, TOWNSEND P A, BARRY S P, et al. Role of the JAK-STAT pathway in myocardial injury [J]. Trends Mol Med, 2007, 13(2): 82-89.
[7] MCCORMICK J, SULEMAN N, SCARABELLI T M, et al. STAT1 deficiency in the heart protects against myocardial infarction by enhancing autophagy [J]. J Cell Mol Med, 2012, 16(2): 386-393.
[8] ZHOU D, DING T, NI B, et al. Hydroxysafflor yellow A mitigated myocardial ischemia/ reperfusion injury by inhibiting the activation of the JAK2/STAT1 pathway [J]. Int J Mol Med, 2019, 44(2): 405-416.
[9] LI G, YANG S Q. Role of PI3K/Akt pathway in protection of cardiomyocytes against hypoxia-reoxy-genation injury induced by hydrogen sulfide post-conditioning [J]. J Third Mil Med Univ(第三军医大学学报), 2011, 33(17): 1803-1807.
[10] SHEN B B, ZHANG S, ZHU Q R, et al. Hydroxysafflor yellow A reduces anoxia / reoxygenation-induced injury in rat cardiomyocytes [J]. Basic Clin Med(基础医学与临床), 2018, 38(4): 480-484.
[11] ROBERTS D J, TAN-SAH V P, SMITH J M, et al. Akt phosphorylates HK-Ⅱ at Thr-473 and increases mitochondrial HK-Ⅱ association to protect cardiomyocytes [J]. J Biol Chem, 2013, 288(33): 23798-23806.
[12] MIN J, WEI C. Hydroxysafflor yellow A cardioprotection in ischemia-reperfusion (I/R) injury mainly via Akt/hexokinase Ⅱ independent of ERK/GSK-3β pathway [J]. Biomed Pharmacother, 2017, 87: 419-426.
[13] WU H, LEI Z, GAO S B, et al. Protective effects of hydroxysafflor yellow A on oxidative damage in H9c2 cells through inhibiting microRNA-1 [J]. J Beijing Univ Tradit Chin Med (北京中医药大学学报), 2018, 41(8): 636-641.
[14] NGUYEN T, NIOI P, PICKETT C B. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress [J]. J Biol Chem, 2009, 284(20): 13291-13295.
[15] NI B, ZHOU D, JING Y, et al. Hydroxysafflor yellow A protects against angiotensin Ⅱ induced hypertrophy [J]. Mol Med Rep, 2018, 18(4): 3649-3656.
[16] FUKUDA S, KAGA S, SASAKI H, et al. Angiogenic signal triggered by ischemic stress induces myocardial repair in rat during chronic infarction [J]. J Mol Cell Cardiol, 2004, 36(4): 547-559.
[17] WEI G, YIN Y, DUAN J, et al. Hydroxysafflor yellow A promotes neovascularization and cardiac function recovery through HO-1/VEGF-A/SDF-1α cascade [J]. Biomed Pharmacother, 2017, 88: 409-420.
[18] CHEN T, CHEN N, PANG N, et al. Hydroxysafflor Yellow A Promotes Angiogenesis via the Angiopoietin 1/ Tie-2 Signaling Pathway [J]. J Vasc Res, 2016, 53(5-6): 245-254.
[19] ZOU J, WANG N, LIU M, et al. Nucleolin mediated pro-angiogenic role of hydroxysafflor yellow A in ischaemic cardiac dysfunction: Post-transcriptional regulation of VEGF-A and MMP-9 [J]. J Cell Mol Med, 2018, 22(5): 2692-2705.
[20] YANG J, WANG R, CHENG X, et al. The vascular dilatation induced by hydroxysafflor yellow A (HSYA) on rat mesenteric artery through TRPV4-dependent calcium influx in endothelial cells [J]. J Ethnopharmacol, 2020, 28(256):112790.
[21] YANG R, ZHAO H X, JI X Y, et al. Activation of myocyte voltage-gated K+ channels is involved in HSYA-induced rat coronary arterial relaxation [J]. Chin J Pathophysiol (中国病理生理杂志), 2020, 36(3): 439-443.
[22] WANG N, HE D, ZHOU Y, et al. Hydroxysafflor yellow A actives BKCa channels and inhibits L-type Ca channels to induce vascular relaxation [J]. Eur J Pharmacol, 2020, 5(870):172873.
[23] WEI X, LIU H, SUN X, et al. Hydroxysafflor yellow A protects rat brains against ischemia-reperfusion injury by antioxidant action[J]. Neurosci Lett, 2005, 386(1): 58-62.
[24] XU H, LIU T, WANG W, et al. Proteomic analysis of hydroxysafflor yellow A against cerebral ischemia/reperfusion injury in rats [J]. Rejuvenation Res, 2019, 22(6): 503-512.
[25] SONG X, SU L, YIN H, et al. Effects of HSYA on the proliferation and apoptosis of MSCs exposed to hypoxic and serum deprivation conditions [J]. Exp Ther Med, 2018, 15(6): 5251-5260.
[26] CHEN S, SUN M, ZHAO X, et al. Neuroprotection of hydroxysafflor yellow A in experimental cerebral ischemia/reperfusion injury via metabolic inhibition of phenylalanine and mitochondrial biogenesis [J]. Mol Med Rep, 2019, 19(4): 3009-3020.
[27] KHATRI R, MCKINNEY A M, SWENSON B, et al. Blood-brain barrier, reperfusion injury, and hemorrhagic transformation in acute ischemic stroke [J]. Neurology, 2012, 25(79):S52-S57.
[28] YANG G, WANG N, SETO S W, et al. Hydroxysafflor yellow A protects brain microvascular endothelial cells against oxygen glucose deprivation/reoxygenation injury: Involvement of inhibiting autophagy via class I PI3K/Akt/mTOR signaling pathway [J]. Brain Res Bull, 2018, 140: 243-257.
[29] LV Y, FU L. The potential mechanism for Hydroxysafflor yellow A attenuating blood-brain barrier dysfunction via tight junction signaling pathways excavated by an integrated serial affinity chromatography and shotgun proteomics analysis approach [J]. Neurochem Int, 2018, 112: 38-48.
[30] LV Y, QIAN Y, FU L, et al. Hydroxysafflor yellow A exerts neuroprotective effects in cerebral ischemia reperfusion-injured mice by suppressing the innate immune TLR4-inducing pathway [J]. Eur J Pharmacol, 2015, 15(769):324-332.
[31] SUN L, YANG L, XU Y W, et al. Neuroprotection of hydroxysafflor yellow A in the transient focal ischemia: inhibition of protein oxidation/nitration, 12/15-lipoxygenase and blood-brain barrier disruption [J]. Brain Res, 2012, 14(1473):227-235.
[32] QI Z, YAN F, SHI W, et al. AKT-related autophagy contributes to the neuroprotective efficacy of hydroxysafflor yellow A against ischemic stroke in rats [J]. Transl Stroke Res, 2014, 5(4): 501-509.
[33] YU L, DUAN Y, ZHAO Z, et al. Hydroxysafflor yellow A (HSYA) improves learning and memory in cerebral ischemia reperfusion-injured rats via recovering synaptic plasticity in the hippocampus [J]. Front Cell Neurosci, 2018, 118(12): 371.
[34] ZHANG N, XING M, WANG Y, et al. Hydroxysafflor yellow A improves learning and memory in a rat model of vascular dementia by increasing VEGF and NR1 in the hippocampus [J]. Neurosci Bull, 2014, 30(3): 417-424.
[35] XING M, SUN Q, WANG Y, et al. Hydroxysafflor yellow A increases BDNF and NMDARs in the hippocampus in a vascular dementia rat model [J]. Brain Res, 2016, 1(1642): 419-425.
[36] ZHANG Z H, YU L J, HUI X C, et al. Hydroxy-safflor yellow A attenuates Aβ-induced inflammation by modulating the JAK2/STAT3/NF-κB pathway [J]. Brain Res, 2014, 14(1563): 72-80.
[37] HAN B, WANG L, FU F, et al. Hydroxysafflor yellow A promotes α-synuclein clearance via regulating autophagy in rotenone-induced Parkinson's disease mice [J]. Folia Neuropathol, 2018, 56(2): 133-140.
[38] WANG T, WANG L, LI C, et al. Hydroxysafflor yellow A improves motor dysfunction in the rotenone-induced mice model of Parkinson's disease [J]. Neurochem Res, 2017, 42(5): 1325-1332.
[39] WANG T, DING Y X, HE J, et al. Hydroxysafflor yellow A attenuates lipopolysaccharide -induced neurotoxicity and neuroinflammation in primary mesencephalic cultures [J]. Molecules, 2018, 23(5): 1210.
[40] LEE M, LI H, ZHAO H, et al. Effects of Hydroxysafflor yellow A on the PI3K/AKT pathway and apoptosis of pancreatic β-cells in type 2 diabetes mellitus rats [J]. Diabetes Metab Syndr Obes, 2020, 9(13): 1097-1107.
[41] ZHAO Y, SUN H, LI X, et al. Hydroxysafflor yellow A attenuates high glucose-induced pancreatic β-cells oxidative damage via inhibiting JNK/c-jun signaling pathway [J]. Biochem Biophys Res Commun, 2018, 505(2): 353-359.
[42] CHEN S, MA J, ZHU H, et al. Hydroxysafflor yellow A attenuates high glucose-induced human umbilical vein endothelial cell dysfunction [J]. Hum Exp Toxicol, 2019, 38(6): 685-693.
[43] GAO S Q, CHANG C, NIU X Q, et al. Topical application of hydroxysafflor yellow a accelerates the wound healing in streptozotocin induced T1DM rats [J]. Eur J Pharmacol, 2018, 823: 72-78.
[44] ZHANG J, LI J, SONG H, et al. Hydroxysafflor yellow A suppresses angiogenesis of hepatocellular carcinoma through inhibition of p38 MAPK phosphorylation [J]. Biomed Pharmacother, 2019, 109: 806-814.
[45] YANG F, LI J, ZHU J, et al. Hydroxysafflor yellow A inhibits angiogenesis of hepatocellular carcinoma via blocking ERK/MAPK and NF-κB signaling pathway in H22 tumor-bearing mice [J]. Eur J Pharmacol, 2015, 5(754): 105-114.
[46] XI S Y, ZHANG Q, LIU C Y, et al. Effects of hydroxy safflower yellow-A on tumor capillary angiogenesis in transplanted human gastric adenocarcinoma BGC-823 tumors in nude mice [J]. J Tradit Chin Med, 2012, 32(2): 243-248.
[47] LIU L, SI N, MA Y, et al. Hydroxysafflor-yellow A induces human gastric carcinoma BGC-823 cell apoptosis by activating peroxisome proliferator-activated receptor gamma (PPARγ) [J]. Med Sci Monit, 2018, 8(24): 803-811.
[48] JIANG M, ZHOU L Y, XU N, et al. Hydroxysafflor yellow A inhibited lipopolysaccharide-induced non-small cell lung cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT/mTOR and ERK/MAPK signaling pathways [J]. Thorac Cancer, 2019, 10(6): 1319-1333.
[49] MA Y, FENG C, WANG J, et al. Hydroxyl safflower yellow A regulates the tumor immune microenvironment to produce an anticancer effect in a mouse model of hepatocellular carcinoma [J]. Oncol Lett, 2019, 17(3): 3503-3510.
[50] GUO X, ZHENG M, PAN R, et al. Hydroxysafflor yellow A (HSYA) targets the platelet-activating factor (PAF) receptor and inhibits human bronchial smooth muscle activation induced by PAF [J]. Food Funct, 2019, 10(8): 4661-4673.
[51] GUO X, ZHENG M, PAN R, et al. Hydroxysafflor yellow A suppresses platelet activating factor-induced activation of human small airway epithelial cells [J]. Front Pharmacol, 2018, 3(9):859.
[52] ZHENG M, GUO X, PAN R, et al. Hydroxysafflor yellow A alleviates ovalbumin-induced asthma in a guinea pig model by attenuateing the expression of inflammatory cytokines and signal transduction [J]. Front Pharmacol, 2019, 5(10):328.
[53] JIN M, WANG L, WU Y, et al. Protective effect of hydroxysafflor yellow A on bleomycin- induced pulmonary inflammation and fibrosis in rats [J]. Chin J Integr Med(中国结合医学杂志), 2018, 24(1): 32-39.
[54] JIN M, XUE C J, WANG Y, et al. Protective effect of hydroxysafflor yellow A on inflammatory injury in chronic obstructive pulmonary disease rats [J]. Chin J Integr Med(中国结合医学杂志), 2019, 25(10): 750-756.
[55] CHAI W, FU L S, LV Y N. The interventional effects of hydroxysafflor yellow A on liver function in hyperlipidemic fatty liver rats [J]. Jiangxi Med J(江西医药), 2018, 53(1): 18-21.
[56] LI W Y, YU Y T, YANG B H. Protective effect of hydroxysafflor yellow A against nonalcoholic fatty liver in high-fat diet induced mice by targeting Sirt1 signaling pathway [J]. Cent South Pharm (中南药学), 2018, 16(11): 1538-1542.
[57] WANG Y R, BAI X Y, LI J M, et al. Effects of hydroxysafflor yellow A on TGF-β1 expression in liver fibrosis of rats [J]. J Bingzhou Med Univ (滨州医学院学报), 2010, 33(6): 405-408.
[58] HE Y, LIU Q, LI Y, et al. Protective effects of hydroxysafflor yellow A (HSYA) on alcohol-induced liver injury in rats [J]. J Physiol Biochem, 2015, 71(1): 69-78.
[59] HU N, DUAN J, LI H, et al. Hydroxysafflor yellow A ameliorates renal fibrosis by suppressing TGF-β1-induced epithelial-to-mesenchymal transition [J]. PLoS One, 2016, 11(4): e0153409.
[60] BAI J, ZHAO J, CUI D, et al. Protective effect of hydroxysafflor yellow A against acute kidney injury via the TLR4/NF-κB signaling pathway [J]. Sci Rep, 2018, 8(1): 9173.
[61] CHENG B F, GAO Y X, LIAN J J, et al. Hydroxysafflor yellow A inhibits IL-1β-induced release of IL-6, IL-8, and MMP-1 via suppression of ERK, NF-κB and AP-1 signaling in SW982 human synovial cells [J]. Food Funct, 2016, 7(11): 4516-4522.
[62] HU Z C, XIE Z J, TANG Q, et al. Hydroxysafflor yellow A (HSYA) targets the NF-κB and MAPK pathways and ameliorates the development of osteoarthritis [J]. Food Funct, 2018, 9(8): 4443-4456.
[63] YAO H Y, CHENG K, WANG L, et al. Effects of hydroxysafflor yellow A on inflammatory factors levels and Notch signaling pathway in osteoarthritis model rats [J]. China Med (中国医药), 2020, 15(6): 927-931.
[64] LIU L, TAO W, PAN W, et al. Hydroxysafflor yellow A promoted bone mineralization and inhibited bone resorption which reversed glucocorticoids-induced osteoporosis [J]. Biomed Res Int, 2018, 2018: 6762146.
[65] MIN F, SUN H, WANG B, et al. Hepatoprotective effects of hydroxysafflor yellow A in D-galactose-treated aging mice [J]. Eur J Pharmacol, 2020, 881: 173214.
[66] LUO M, HUANG J C, YANG Z Q, et al. Hydroxysafflor yellow A exerts beneficial effects by restoring hormone secretion and alleviating oxidative stress in polycystic ovary syndrome mice [J]. Exp Physiol, 2020, 105(2): 282-292.
[67] SHI M X, GUO Q, HUANG Y R, et al. Pharmacokinetics of hydroxysafflor yellow A water-in-oil nanoemulsion [J]. Chin Pharm J(中国药学杂志), 2018, 53(24): 2108-2112.
[68] HUANG Y R, ZHANG J P, SHI M X, et al. Pharmacokinetic characteristics of oral hydroxysafflor yellow A in rats[J]. Chin Pharm J (中国药学杂志), 2020, 55(1): 39-43.
PDF(1127 KB)

Accesses

Citation

Detail

段落导航
相关文章

/